Applied Genetic Technologies Corporation (AGTC)

Last Closing Price: 0.28 (2022-09-26)

Company Description

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.50M
Net Income (Most Recent Fiscal Year) $-57.83M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.26
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -12945.20%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -98.79%
Return on Assets (Trailing 12 Months) -60.15%
Current Ratio (Most Recent Fiscal Quarter) 2.73
Quick Ratio (Most Recent Fiscal Quarter) 2.73
Debt to Common Equity (Most Recent Fiscal Quarter) 0.24
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $2.01
Earnings per Share (Most Recent Fiscal Quarter) $-0.33
Earnings per Share (Most Recent Fiscal Year) $-1.77
Diluted Earnings per Share (Trailing 12 Months) $-1.46
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 50.73M
Free Float 48.65M
Market Capitalization $14.46M
Average Volume (Last 20 Days) 0.54M
Beta (Past 60 Months) 1.26
Percentage Held By Insiders (Latest Annual Proxy Report) 4.10%
Percentage Held By Institutions (Latest 13F Reports) 22.05%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%